TFAP2C |
HeLa S3 (cervical adenocarcinoma) |
None |
Permissive
Robust
|
Homo sapiens |
wgEncodeEH000686
|
MA0524.2
...
|
TFAP2C |
WA09 (embryonic stem cells) |
BMP4 for 3 day |
Permissive
|
Homo sapiens |
GSE105081
...
|
MA0524.2
...
|
TFAP2C |
WA09 (embryonic stem cells) |
BMP4 for 3 day |
Permissive
Robust
|
Homo sapiens |
GSE105081
...
|
MA0524.2
...
|
TFAP2C |
UCLA1 hESCs |
PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions; |
Permissive
Robust
|
Homo sapiens |
GSE101074
...
|
MA0524.2
...
|
TFAP2C |
UCLA1 hESCs |
PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions; |
Permissive
Robust
|
Homo sapiens |
GSE101074
...
|
MA0524.2
...
|
TFAP2C |
UCLA1 hESCs |
PasNumber:p16+ p37; Treatment: Naive(5iLAF) conditions; |
Permissive
Robust
|
Homo sapiens |
GSE101074
...
|
MA0524.2
...
|
TFAP2C |
UCLA1 hESCs |
PasNumber: p33; Treatment: 5 days in 5iLAF; |
Permissive
Robust
|
Homo sapiens |
GSE101074
...
|
MA0524.2
...
|
TFAP2C |
UCLA1 hESCs |
PasNumber: p28; CellType: Prime UCLA1 hESSCs; |
Permissive
Robust
|
Homo sapiens |
GSE101074
...
|
MA0524.2
...
|
TFAP2C |
UCLA1 hESCs |
PasNumber: p28; CellType: Prime UCLA1 hESSCs; |
Permissive
Robust
|
Homo sapiens |
GSE101074
...
|
MA0524.2
...
|
TFAP2C |
UCLA1 hESCs |
PasNumber: p28; CellType: Prime UCLA1 hESSCs; |
Permissive
Robust
|
Homo sapiens |
GSE101074
...
|
MA0524.2
...
|
TFAP2C |
UCLA1 hESCs |
PasNumber: p52; Genotype: TFAP2C -/-; Treatment: No Induc; |
Permissive
|
Homo sapiens |
GSE101074
...
|
MA0524.2
...
|
TFAP2C |
UCLA1 hESCs |
PasNumber: p52; Genotype: TFAP2C -/-; Treatment: transduced construct that allows doxycycline inducible expression of TFAP2C; |
Permissive
Robust
|
Homo sapiens |
GSE101074
...
|
MA0524.2
...
|
TFAP2C |
UCLA1 hESCs |
PasNumber: p52; Genotype: TFAP2C -/-; Treatment: transduced construct that allows doxycycline inducible expression of TFAP2C; |
Permissive
Robust
|
Homo sapiens |
GSE101074
...
|
MA0524.2
...
|
TFAP2C |
MCF7 (Invasive ductal breast carcinoma) |
Treatment: with Estrogen; |
Permissive
Robust
|
Homo sapiens |
GSE117492
...
|
MA0524.2
...
|
TFAP2C |
MCF7 (Invasive ductal breast carcinoma) |
Treatment: with Estrogen +1,6-Hexanediol; |
Permissive
Robust
|
Homo sapiens |
GSE117492
...
|
MA0524.2
...
|
TFAP2C |
A375 (malignant melanoma) |
DMSO |
Permissive
Robust
|
Homo sapiens |
GSE41234
|
MA0524.2
...
|
TFAP2C |
ZHBTc4-TS (trophoblast stem cells) |
|
Permissive
Robust
|
Mus musculus |
GSE51511
...
|
MA0524.2
...
|
TFAP2C |
mammary tumor |
|
Permissive
Robust
|
Mus musculus |
GSE61394
...
|
MA0524.2
...
|
TFAP2C |
MCF7 (Invasive ductal breast carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE21234
|
MA0524.2
...
|
TFAP2C |
BT-474 (breast invasive ductal carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE36351
|
MA0524.2
...
|
TFAP2C |
MCF7 (Invasive ductal breast carcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE36351
|
MA0524.2
...
|
TFAP2C |
MDA-MB-453 (breast adenocarcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE36351
|
MA0524.2
...
|
TFAP2C |
SK-BR-3 (breast adenocarcinoma) |
|
Permissive
Robust
|
Homo sapiens |
GSE36351
|
MA0524.2
...
|
TFAP2C |
MCF7 (Invasive ductal breast carcinoma) |
E2 |
Permissive
Robust
|
Homo sapiens |
GSE23852
|
MA0524.2
...
|
TFAP2C |
MCF7 (Invasive ductal breast carcinoma) |
ETOH |
Permissive
Robust
|
Homo sapiens |
GSE23852
|
MA0524.2
...
|